Temsirolimus

Kidney Neoplasms
Treatment
2 FDA approvals
12 Active Studies for Temsirolimus

What is Temsirolimus

TemsirolimusThe Generic name of this drug
Treatment SummaryTemsirolimus, also known as Torisel, is a medication used to treat renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals and approved by the FDA in 2007 and the European Medicines Agency (EMEA) in November of the same year.
Toriselis the brand name
image of different drug pills on a surface
Temsirolimus Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Torisel
Temsirolimus
2007
5

Approved as Treatment by the FDA

Temsirolimus, otherwise called Torisel, is approved by the FDA for 2 uses including Advanced Renal Cell Carcinoma (aRCC) and Kidney Neoplasms .
Advanced Renal Cell Carcinoma (aRCC)
Kidney Neoplasms

Effectiveness

How Temsirolimus works in the bodyTemsirolimus stops cell division by targeting an intracellular protein called mTOR. When it binds to the protein FKBP-12, it prevents mTOR from activating the pathways needed for cell division. This stops tumor cells from growing. In vitro studies on renal cell cancer also showed that temsirolimus blocked the production of factors that contribute to blood vessel growth, which could be beneficial for cancer patients.

When to interrupt dosage

The suggested dosage of Temsirolimus is contingent upon the diagnosed affliction. The quantity of dosage varies, as indicated by the method of delivery featured in the table beneath.
Condition
Dosage
Administration
Kidney Neoplasms
, 30.0 mg, 25.0 mg/mL
Intravenous, , Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Kit - Intravenous

Warnings

Temsirolimus Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Temsirolimus.
Common Temsirolimus Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Temsirolimus is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Temsirolimus.
Abetimus
Major
The risk or severity of adverse effects can be increased when Temsirolimus is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Temsirolimus is combined with Acteoside.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Temsirolimus.
Temsirolimus Toxicity & Overdose RiskTemsirolimus has been tested on cancer patients in early trials with doses as high as 220 mg/m2. Taking doses greater than 25 mg can increase the risk of serious problems such as blood clots, holes in the intestine, lung disease, seizures, and mental health issues.
image of a doctor in a lab doing drug, clinical research

Temsirolimus Novel Uses: Which Conditions Have a Clinical Trial Featuring Temsirolimus?

Fifteen studies are being conducted to evaluate the potential of Temsirolimus to treat Advanced Renal Cell Carcinoma (aRCC).
Condition
Clinical Trials
Trial Phases
Kidney Neoplasms
13 Actively Recruiting
Not Applicable, Phase 2, Phase 1

Temsirolimus Reviews: What are patients saying about Temsirolimus?

5Patient Review
9/4/2010
Temsirolimus for Cancer Involving the Kidney Cells
I was diagnosed with kidney cancer in 2004 and have had surgeries on both kidneys. I have been on IL-2, Sutent, Trial Clinic. I have been on Torisel for 30 months with stable results every 3-4 under a CT/MRI.
3Patient Review
6/23/2008
Temsirolimus for Cancer Involving the Kidney Cells
I contracted pneumonia
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about temsirolimus

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is temsirolimus an immunotherapy?

"The mTOR inhibitors are also immunosuppressants and are used clinically to prevent rejection following solid-organ transplant. However, researchers are also working on developing new immunotherapies that could be used to treat immunoresponsive tumours, such as RCC and melanoma."

Answered by AI

Is temsirolimus the same as sirolimus?

"Temsirolimus and sirolimus are both drugs that inhibit mammalian target of rapamycin. Temsirolimus is a prodrug of sirolimus, meaning that it is converted into sirolimus once it is inside the body."

Answered by AI

Is temsirolimus a chemotherapy?

"The drug Temsirolimus is sold under the trade name Torisel. In some cases, doctors and other health care professionals may refer to the drug by its generic name, Temsirolimus, instead of its trade name, Torisel."

Answered by AI

What is Temsirolimus used for?

"Temsirolimus is a medication used to treat advanced renal cell carcinoma, a type of cancer that begins in the kidney. Temsirolimus works by blocking the action of the abnormal protein that tells the cancer cells to multiply, which may help slow the growth of tumors."

Answered by AI

Clinical Trials for Temsirolimus

Image of City of Hope Medical Center in Duarte, United States.

RP2 + Tivozanib for Kidney Cancer

18+
All Sexes
Duarte, CA
This phase II trial tests the effect of RP2 and tivozanib in treating patients with renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that is growing, spreading, or getting worse (progressive) after receiving immunotherapy with immune checkpoint inhibitors (ICIs). RP2 is a herpes simplex virus (a viral infection commonly known as the "cold sore virus") that has been changed to infect and destroy tumor cells and to activate (turn on) the human immune system to attack the tumor cells. Tivozanib hydrochloride blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Tivozanib hydrochloride is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Giving RP2 and tivozanib may be safe, tolerable, and/or effective in treating patients with metastatic renal cell cancer that has progressed after receiving immunotherapy with ICIs.
Phase 2
Waitlist Available
City of Hope Medical Center (+1 Sites)Charles B Nguyen
Image of Columbia University Irving Medical Center in New York, United States.

XL092 + Nivolumab for Kidney Cancer

18+
All Sexes
New York, NY
The study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of zanzalintinib (XL092) alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatment will continue until progression by RECIST 1.1, toxicity, or other reasons as appropriate.
Phase 2
Recruiting
Columbia University Irving Medical Center (+1 Sites)Karie Runcie, MDExelixis
Image of City of Hope Medical Center in Duarte, United States.

CBM588 + Nivolumab + Ipilimumab for Advanced Kidney Cancer

18+
All Sexes
Duarte, CA
This phase I trial tests the safety, side effects, best dose, and effectiveness of CBM588 in combination with nivolumab and ipilimumab in treating patients with kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). CBM588 is a live biotherapeutic that may help improve the effects of immunotherapy. Nivolumab and ipilimumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread by enhancing the ability of the body's immune cells to attack tumor cells. CBM588 in combination with nivolumab and ipilimumab may be safe, tolerable, and/or effective in treating patients with advanced stage kidney cancer.
Phase 1
Recruiting
City of Hope Medical CenterAlex Chehrazi-Raffle, MDOsel, Inc.
Image of Mayo Clinic in Florida in Jacksonville, United States.

Nivolumab for Cancer

18+
All Sexes
Jacksonville, FL
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends and familiar surroundings for many hours per day. This separation adds to the physical, emotional, social, and financial burden for patients and their families. Traveling to and from medical facilities costs time, money, and effort and can be a disadvantage to patients living in rural areas, those with low incomes or poor access to transport. Studies have shown that cancer patients often feel more comfortable and secure being cared for in their own home environments. SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve the quality of life in cancer patients.
Phase 2
Recruiting
Mayo Clinic in FloridaRoxana S. Dronca, M.D.
Have you considered Temsirolimus clinical trials? We made a collection of clinical trials featuring Temsirolimus, we think they might fit your search criteria.Go to Trials
Have you considered Temsirolimus clinical trials? We made a collection of clinical trials featuring Temsirolimus, we think they might fit your search criteria.Go to Trials
Image of University of California, San Francisco in San Francisco, United States.

Predictive Marker Analysis for Prostate Cancer

18+
Male
San Francisco, CA
This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial carcinoma. Whenever possible, a new bone lesion or new/progressing soft tissue lesion will be chosen for biopsy as opposed to radiographically stable lesion. Patients will be enrolled in into one of several parallel cohorts based upon disease status or type and the planned systemic therapy following baseline tumor biopsy: (A) Androgen signaling inhibition, (B) Immunotherapy, (C) Radiotherapy, (D) Targeted Therapy/Investigational therapeutic, (E) DNA damage response pathway, (F) Aggressive variant disease, (G1) Castration-sensitive ADT naïve and ADT \< 3 months), or (G2) Castration-sensitive pre-treated with sub-optimal PSA nadir \>0.2 ng/ml, (R) metastatic renal cell carcinoma and metastatic and (U) urothelial carcinoma.
Waitlist Available
Has No Placebo
University of California, San FranciscoRahul Aggarwal, MDStrata Oncology
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security